Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
The results announced today from the fifth cohort of the RESOLVE trial, for treatment of EoE, are derived from 12, 4 mg injections of EP-104GI (total dose of 48 mg) administered to the lower ...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...
PharmiWeb7d
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...
WCMH Columbus on MSN5d
Hospitals see spike in ‘walking pneumonia’ cases
Nationwide Children’s Hospital is monitoring an uptick in mycoplasma pneumonia cases.   According to the U.S. Centers for Disease Control and Prevention, cases ...
Big News Network.com1d
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds ... and Relief plans to seek qualified infectious disease ...
Pharmabiz1d
Relief Therapeutics announces positive final results of RLF-TD011 trial in epidermolysis bullosa
Relief Therapeutics announces positive final results of RLF-TD011 trial in epidermolysis bullosa: Geneva Tuesday, November 12, 2024, 10:00 Hrs [IST] Relief Therapeutics Holding SA ...
Eupraxia Pharmaceuticals Announces That It Has Closed A Non-Brokered Private Placement Of C$44.5 Million
In connection with the closing of the Private Placement, the Company also announces that it has terminated the Company's C$12 million convertible debt facility (the "Convertible Debt Facility"). The ...
T-Net7d
Eupraxia Closes $44.5M Private Placement Financing, Appoints Former Brookfield Senior Partner to Board
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...
T-Net14d
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...
Parade on MSN13d
Roll up Your Sleeves! These Are the 10 Best Ways To Prevent the Flu
Of course, you absolutely should get a flu shot—it's still the most effective way to prevent the flu (or, at least, to ...
Finanznachrichten20d
Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, ...